Eli Lilly and Company (NYSE: LLY) today announced additional details regarding the Medicare GLP-1 Bridge* program taking effect July 1, 2026. Under the program, Medicare Part D patients may be able to access Foundayo (orforglipron) or Zepbound (tirzepatide) KwikPen for single-patient-use for weight management.

CMS says the 18-month demonstration will expand access to select weight-loss drugs while the agency gathers data on uptake, outcomes and program operations.

Medicare Part D is introducing important prescription drug cost updates in 2026, including higher deductibles, a new out-of-pocket cap, and expanded savings on selected medications that could significantly affect beneficiaries' healthcare budgets.

Each year, Medicare beneficiaries are given the opportunity to select a new plan for the upcoming year during the Open Enrollment Period. This year, Open Enrollment begins on October 15 and will run until December 7, 2025 – for most people, this will be ...

Currently, there‘s no universal Medicare drug price list available, as drug costs and availability vary according to the private insurer administering the Part D prescription drug plan. Contact Part D prescription drug plan providers to view a Medicare ...